UMN-03 manufacturing agreement based on Crucell’s PER.C6 platform.

DSM Biologics and UMN Pharma signed a biopharmaceutical manufacturing agreement based on Crucell’s PER.C6® manufacturing platform. DSM Biologics will provide UMN Pharma with process development services, analytical development services, and cGMP manufacturing for UMN Pharma’s UMN-03 fusion protein.

UMN Pharma developed the UMN-03 fusion protein for the treatment of muscular dystrophy and metabolic diseases, such as obesity and type 2 diabetes.

The services will be provided out of DSM Biologics’ manufacturing facility in Groningen. The Agreement follows the license agreement that was signed in March, 2006 between UMN Pharma, DSM Biologics, and Crucell.

Previous articleIndependent Predictive Marker of Potential Prostate Cancer Recurrence Found
Next articleEnzon Adds Second Application Approval for Candidate Related to Infections in Low-Level MBL Patients